Tag Archive for: macrophage cell therapy

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

/in

New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation Comes as Resolution progresses its Phase I/II EMERALD study of […]

Read more

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

/in

EMERALD Study will investigate safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis Edinburgh and London, UK, 27 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces it has received approval from the U.K. Medicines and Healthcare […]

Read more